Waters reports Q2 EPS $2.95, consensus $2.94

Reports Q2 revenue $771.33M, consensus $749.51M. “Our team continues to execute extremely well and we delivered excellent results again this quarter, driven by robust instrument replacement trends-particularly among large pharma and CDMO customers,” said Udit Batra, president and CEO, Waters (WAT) Corporation. “Our performance reflects strong execution against our commercial growth initiatives, rapid uptake of our new products, and contribution from incremental growth vectors such as GLP-1s, PFAS and generics. As a result, we are raising our full-year sales and earnings guidance.”